Correlation Between Moleculin Biotech and Tonix Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Moleculin Biotech and Tonix Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Moleculin Biotech and Tonix Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Moleculin Biotech and Tonix Pharmaceuticals Holding, you can compare the effects of market volatilities on Moleculin Biotech and Tonix Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Moleculin Biotech with a short position of Tonix Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Moleculin Biotech and Tonix Pharmaceuticals.

Diversification Opportunities for Moleculin Biotech and Tonix Pharmaceuticals

0.12

Correlation Coefficient

Moleculin Biotech  Tonix Pharmaceuticals

Average diversification

The 3 months correlation between Moleculin and Tonix is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Moleculin Biotech and Tonix Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tonix Pharmaceuticals and Moleculin Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Moleculin Biotech are associated (or correlated) with Tonix Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tonix Pharmaceuticals has no effect on the direction of Moleculin Biotech i.e., Moleculin Biotech and Tonix Pharmaceuticals go up and down completely randomly.

Pair Corralation between Moleculin Biotech and Tonix Pharmaceuticals

Given the investment horizon of 90 days Moleculin Biotech is expected to under-perform the Tonix Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Moleculin Biotech is 4.42 times less risky than Tonix Pharmaceuticals. The stock trades about -0.1 of its potential returns per unit of risk. The Tonix Pharmaceuticals Holding is currently generating about 0.35 of returns per unit of risk over similar time horizon. If you would invest  13.00  in Tonix Pharmaceuticals Holding on September 17, 2024 and sell it today you would earn a total of  37.15  from holding Tonix Pharmaceuticals Holding or generate 285.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Moleculin Biotech  vs.  Tonix Pharmaceuticals Holding

Moleculin Biotech

Risk-Adjusted Performance

0 of 100

Weak

Over the last 90 days Moleculin Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Moleculin Biotech is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Tonix Pharmaceuticals

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Tonix Pharmaceuticals Holding are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Tonix Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Moleculin Biotech and Tonix Pharmaceuticals

The main advantage of trading using opposite Moleculin Biotech and Tonix Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Moleculin Biotech position performs unexpectedly, Tonix Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will offset losses from the drop in Tonix Pharmaceuticals' long position.

The idea behind Moleculin Biotech and Tonix Pharmaceuticals Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.